Navigation Links
Stemline Therapeutics, Inc. Announces Presentations of SL-401 Updated Clinical Trial Results in Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and SL-101 Preclinical Efficacy Data Against Hodgkin's Lymphoma at
Date:12/7/2012

Abstract #: 2768
Lead Author: Christopher Brooks, Ph.D., Stemline Therapeutics, Inc.
Session: 625. Lymphoma - Pre-Clinical - Chemotherapy and Biologic Agents: Poster II
Date/Time: Sunday, December 9, 2012; 6:00 – 8:00pm ET
Location: Hall B1-B2 (Georgia World Congress Center)

A copy of the above referenced abstracts can be viewed online through the ASH website at www.hematology.org.

About Stemline Therapeutics, Inc.
Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company developing novel oncology therapeutics that target both cancer stem cells (CSCs) as well as the tumor bulk. Among Stemline's drug candidates are SL-401 and SL-701, both of which have demonstrated single agent clinical activity in Phase 1/2 studies of advanced cancer patients. In a multicenter Phase 1/2 trial in patients with advanced acute myeloid leukemia (AML) and other hematologic malignancies including blastic plasmacytoid dendritic cell neoplasm (BPDCN), SL-401 demonstrated single agent activity, including durable complete responses (CRs), and an overall survival (OS) improvement relative to historical data in the most heavily pretreated AML patients. SL-401 also induced two additional CRs in patients with relapsed/refractory BPDCN, a rare lymphoma. In addition, SL-401 was well-tolerated and was not toxic to the bone marrow. SL-401 is being advanced into later stage trials in advanced BPDCN and AML. In Phase 1/2 trials, Stemline's second clinical stage therapeutic, SL-701, has demonstrated single agent activity including durable CRs and partial responses (PRs) in adult patients with refractory or recurrent glioblastoma and pediatric patients with malignant glioma, as well as an OS benefit in adult patients with refractory or recurrent glioblastoma compared with historical data. SL-701 is now poised for later stage trials in pediatric and adult patients with advanced brain cancer. Stemline is also
'/>"/>

SOURCE Stemline Therapeutics, Inc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Stemline Therapeutics, Inc. to Present at the Oppenheimer 22nd Annual Healthcare Conference
2. Stemline Therapeutics, Inc. Announces Two Poster Presentations of SL-401 Efficacy Data Against Lymphoid Cancers at the 53rd Annual Meeting of the American Society of Hematology (ASH)
3. Cell Therapeutics, Inc. (CTI) to Present at Jefferies 2012 Global Healthcare Conference
4. Cell Therapeutics, Inc. (CTI) to Report Second Quarter Financial Results on August 1
5. Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones
6. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
7. ISPE Announces 2012 Award Winners at Global Annual Meeting
8. Sequenom, Inc. Announces Issuance Of Patent For Methods Of Detecting Fetal Aneuploidy
9. Inovio Pharmaceuticals Announces Positive Interim Results in Phase II Leukemia Trial
10. T1D Exchange Announces Appointment of Dana Ball as Chief Executive Officer
11. Saladax Biomedical, Inc. Announces the Formation of a CLIA Laboratory As Part of the Companys Commercialization Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ), the ... a company overview at the Nomura Biotechnology Conference on Thursday, ... Boston, MA. A live webcast of ... section of the Company,s website, www.isispharm.com .  A replay ... and will be archived for a limited time. ...
(Date:10/30/2014)... challenges in the development of quantum technologies has been ... paper published today (28 October) in Nature Communications ... make a new type of flexibly designed microscopic trap ... sensors and specialised superfast computers, often depend on harnessing ... trapping these tiny particles are hugely problematic because of ...
(Date:10/27/2014)... The new research report, “Gas ... Medium), Sub-type (Primary & Secondary), and End-User (Transmission ... & Power Generation) - Trends and Forecasts to ... analysis and forecasting of the market size. , ... 52 Figures spread through 146 Pages and in-depth ...
(Date:10/27/2014)... , Oct. 27, 2014 Kalorama Information ... recent Ebola concern in the United States ... virus.  The healthcare market researcher said the FDA,s Emergency Use ... vitro diagnostic tests for the detection of the Ebola ... proved useful.  Kalorama routinely assess the IVD industry and ...
Breaking Biology Technology:Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4Kalorama: PCR The Go-to Test in Ebola Fight 2Kalorama: PCR The Go-to Test in Ebola Fight 3
... October 6, 2010 ... ... var shortURL ... longUrl, so we need to grab the first one. for (var r in data.results) { first_result = ...
... tiaras to anklets are treasures but these gemstones inside ... Reserve University researchers are building implants made of diamond ... and electrical changes in the brain of patients suffering ... movement in the paralyzed. The work of Heidi ...
... Oct. 4 issue of the high-impact journal, Applied ... the University of Cincinnati and start-up company Gamma Dynamics ... electronic devices. This patent-pending electrofluidics breakthrough by the ... partner companies Gamma Dynamics, Dupont and Sun Chemical follows ...
Cached Biology Technology:Elsevier Introduces Article-Based Publishing to Increase Publication Speed 2Elsevier Introduces Article-Based Publishing to Increase Publication Speed 3Elsevier Introduces Article-Based Publishing to Increase Publication Speed 4Elsevier Introduces Article-Based Publishing to Increase Publication Speed 5Elsevier Introduces Article-Based Publishing to Increase Publication Speed 6Elsevier Introduces Article-Based Publishing to Increase Publication Speed 7Elsevier Introduces Article-Based Publishing to Increase Publication Speed 8Gem of an idea: A flexible diamond-studded electrode implanted for life 2Gem of an idea: A flexible diamond-studded electrode implanted for life 3Breakthrough e-display means electronics with high speed, high readability and low power usage 2Breakthrough e-display means electronics with high speed, high readability and low power usage 3Breakthrough e-display means electronics with high speed, high readability and low power usage 4
(Date:10/31/2014)... steps involved in programmed cell death, offering new targets ... neurodegenerative diseases. , The research teams from the ... the three-dimensional structure of a key cell death protein ... it causes cell death. Their studies were published in ... Proceedings of the National Academy of Sciences . ...
(Date:10/31/2014)... 2014  HITLAB SM , a healthcare innovation ... inaugural HITLAB Innovators Summit SM on December ... will partner with the Clinton Foundation,s Health Matters ... Columbia Business School Alumni Club of ... and Operations Research, bringing together leaders in healthcare ...
(Date:10/30/2014)... When most animals begin life, cells immediately begin accepting ... organ. However, mammals, including humans, are special. The cells ... choice – to become the protective placenta or to ... critical first step that research from Michigan State University ... current issue of PLOS Genetics , ...
Breaking Biology News(10 mins):A matter of life and death: Cell death proteins key to fighting disease 2HITLAB Announces Inaugural HITLAB Innovators Summit 2HITLAB Announces Inaugural HITLAB Innovators Summit 3Identifying the source of stem cells 2
... from brake linings and mining operations can affect salmon ... a Washington State University researcher. Jenifer McIntyre found the ... they won,t detect a compound that ordinarily alerts them ... is not getting the information it needs to make ...
... Switzerland. Research to be presented at the Annual Meeting of ... foremost society for research into all aspects of eating and ... reduces the quality of sleep in rats. Using radio-telemetry, ... consumed a high fat diet for 8 weeks. Compared to ...
... debilitating illnesses one can develop. Currently, the disease afflicts 6.5 ... to between 11 and 16 million, or 1 in 85 ... one to grow forgetful, confused and, eventually, catatonic. Recently approved ... consensus on the underlying mechanism of the disease. "We ...
Cached Biology News:Copper making salmon prone to predators 2Small molecule may play big role in Alzheimer's disease 2Small molecule may play big role in Alzheimer's disease 3Small molecule may play big role in Alzheimer's disease 4
Rabbit polyclonal to Warfarin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to KLH...
Rabbit polyclonal to MA2 ( Abpromise for all tested applications). entrezGeneID: 10687 SwissProtID: Q9UL42...
Mouse monoclonal [YPF19] to Yersinia pestis ( Abpromise for all tested applications)....
DDO Immunogen: DDO (NP_003640, 270 a.a. ~ 370 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: